Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP3 prostanoid receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 18, 2002, Pages 2583-2586

  Gallant, M ^a   Carriere M C ^a   Chateauneuf, A ^a   Denis, D ^a   Gareau, Y ^a   Godbout, C ^a   Greig, G ^a   Juteau, H ^a   Lachance, N ^a   Lacombe, P ^a   Lamontagne, S ^a   Metters, K M ^a   Rochette, C ^a   Ruel, R ^a   Slipetz, D ^a   Sawyer, N ^a   Tremblay, N ^a   Labelle, M ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; SULFINAMIDE;

ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; STRUCTURE ACTIVITY RELATION;

HUMANS; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 18644374700     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00518-8     Document Type: Article

References (14)

1. Abramovitz M., Adam A., Boie Y., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N.M., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., Metters K.M. Biochim. Biophys. Acta. 285:2000;1483.
2. Kiryiama A., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Br. J. Pharmacol. 122:1997;217.
3. (a) Sugimoto Y., Narumiya S., Ichikawa A. Prog. Lipid. Res. 39:2000;289 (b) Narumiya S., Sugimoto Y., Ushikubi F. Physiol. Rev. 79:1999;1193 (c) Coleman R.A., Smith W.L., Narumiya S. Pharmacol. Rev. 46:1994;205.
4. (a) Sugimoto Y., Narumiya S., Ichikawa A. Prog. Lipid. Res. 39:2000;289 (b) Narumiya S., Sugimoto Y., Ushikubi F. Physiol. Rev. 79:1999;1193 (c) Coleman R.A., Smith W.L., Narumiya S. Pharmacol. Rev. 46:1994;205.
5. (a) Sugimoto Y., Narumiya S., Ichikawa A. Prog. Lipid. Res. 39:2000;289 (b) Narumiya S., Sugimoto Y., Ushikubi F. Physiol. Rev. 79:1999;1193 (c) Coleman R.A., Smith W.L., Narumiya S. Pharmacol. Rev. 46:1994;205.
6. Shimazaki Y., Kameo K., Tanami T., Tanaka H., Ono N., Kiuchi Y., Okamoto S., Sato F., Ichikawa A. Bioorg. Med. Chem. 8:2000;353.
7. 3-III subtype was used for the binding assay.
8. Ashton W.T., Chang L.L., Flanagan K.L., Hutchins S.M., Naylor E.M., Chakravarty P.K., Patchett A.A., Greenlee W.J., Chen T.B. J. Med. Chem. 37:1994;2808.
9. -5 M in 0.5% DMSO), and incubated at 37 °C for 10 min. The reaction was terminated by boiling the samples for 3 min and cAMP was measured by cAMP SPA assay (Amersham).
10. Pelletier J.C., Hesson D.P. Synlett. 11:1995;1141.
11. Belletire J.L., Spletzer E.G. Tetrahedron Lett. 27:1986;131.
12. Rathke M.W., Linbert A. J. Am. Chem. Soc. 93:1971;2318.
13. Friesen R.W., Giroux A. Tetrahedron Lett. 34:1993;1867.
14. Weinstein B., Ho T.N.S., Fukura R.T., Angell E.C. Synth. Commun. 6:1976;17.